Pharmacyclics/Janssen ibrutinib NDA sparks high hopes
This article was originally published in Scrip
Executive Summary
The quick submission of the new drug application (NDA) for ibrutinib, revealed on 10 July by biotech Pharmacyclics and its partner Janssen Research & Development, sparked excitement on Wall Street, which holds great expectations for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor.